Abstract
Abstract Targeting the endocrine axis remains a mainstay of the treatment of many breast and most prostate cancers. Recent studies indicate that these tumors commonly remain nuclear steroid hormone receptor driven once endocrine resistance ensues. Multiple novel, rationally designed, agents are in development that are showing promise in the treatment of these diseases including drugs targeting p110beta, AKT, TORC1/2, as well as drugs targeting PARP, bromodomain proteins BRD2-4 and heat shock proteins including HSP90 and HSP27. Furthermore novel agents targeting the amino terminus of the androgen receptor and degrading these receptors are being evaluated. This presentation will describe challenges and solutions to their successful drug combination development. Citation Format: Johann S. De Bono. Combination strategies. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr CN06-04.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
